Acknowledgement
Supported by : Korean Society of Cardiology
References
- Cohn LH, Collins JJ Jr, Rizzo RJ, Adams DH, Couper GS, Aranki SF. Twenty-year follow-up of the Hancock modified orifice porcine aortic valve. Ann Thorac Surg 1998;66(6 Suppl):S30-4. https://doi.org/10.1016/S0003-4975(98)01105-9
- Jamieson WR, Burr LH, Munro AI, Miyagishima RT. Carpentier-Edwards standard porcine bioprosthesis: a 21-year experience. Ann Thorac Surg 1998;66(6 Suppl):S40-3. https://doi.org/10.1016/S0003-4975(98)01124-2
- Schoen FJ. Cardiac valve prostheses: review of clinical status and contemporary biomaterials issues. J Biomed Mater Res 1987;21(A1 Suppl):91-117.
- Colli A, Gherli T, Mestres CA, Pomar JL. Degeneration of native and tissue prosthetic valve in aortic position: do statins play an effective role in prevention? Int J Cardiol 2007;116:144-52. https://doi.org/10.1016/j.ijcard.2006.03.047
- Farivar RS, Cohn LH. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg 2003;126:969-75. https://doi.org/10.1016/S0022-5223(03)00708-6
- Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg 2005;79:1072-80. https://doi.org/10.1016/j.athoracsur.2004.06.033
- Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205-9. https://doi.org/10.4070/kcj.2016.0214 www.e-kcj.org
- Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693-5. https://doi.org/10.1016/S0002-9149(01)01821-5
- Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002;106:1077-82. https://doi.org/10.1161/01.CIR.0000027567.49283.FF
- Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000;101:2497-502. https://doi.org/10.1161/01.CIR.101.21.2497
- Black AE, Sinz MW, Hayes RN, Woolf TF. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 1998;26:755-63.
- Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-30. https://doi.org/10.1016/S0735-1097(02)02496-8
- Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002;359:1125-6. https://doi.org/10.1016/S0140-6736(02)08161-8
- Lorusso R, Corradi D, Maestri R, et al. Atorvastatin attenuates postimplant tissue degeneration of cardiac prosthetic valve bovine pericardial tissue in a subcutaneous animal model. Int J Cardiol 2010;141:68-74. https://doi.org/10.1016/j.ijcard.2008.11.174
- Demer LL. Cholesterol in vascular and valvular calcification. Circulation 2001;104:1881-3. https://doi.org/10.1161/circ.104.16.1881
- Vyavahare NR, Jones PL, Hirsch D, Schoen FJ, Levy RJ. Prevention of glutaraldehyde-fixed bioprosthetic heart valve calcification by alcohol pretreatment: further mechanistic studies. J Heart Valve Dis 2000;9:561-6.
- Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19:1218-22. https://doi.org/10.1161/01.ATV.19.5.1218
- Schmermund A, Mohlenkamp S, Erbel R. The latest on the calcium story. Am J Cardiol 2002;90(10C):12L-4L. https://doi.org/10.1016/S0002-9149(02)02955-7
- Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation 2001;103:1522-8. https://doi.org/10.1161/01.CIR.103.11.1522
- Yildirir A, Muderrisoglu H. Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol 2004;2:309-18. https://doi.org/10.2174/1570161043385475
- Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002;105:2660-5. https://doi.org/10.1161/01.CIR.0000017435.87463.72
- Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9. https://doi.org/10.1126/science.286.5446.1946
- Osman L, Yacoub MH, Latif N, Amrani M, Chester AH. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 2006;114(1 Suppl):I547-52.
Cited by
- Rosuvastatin attenuates bioprosthetic heart valve calcification vol.158, pp.3, 2017, https://doi.org/10.1016/j.jtcvs.2018.12.042
- Commentary: Tissue valves—One more reason to stay on top of your cholesterol vol.158, pp.3, 2017, https://doi.org/10.1016/j.jtcvs.2019.01.003